Wallentin Medical Consulting ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 5.2% 3.7% 3.0% 2.7%  
Credit score (0-100)  0 43 50 57 59  
Credit rating  N/A BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 666 1,246 622 655  
EBITDA  0.0 666 1,246 622 655  
EBIT  0.0 664 1,236 608 642  
Pre-tax profit (PTP)  0.0 664.3 1,224.6 601.2 639.6  
Net earnings  0.0 518.1 953.3 467.9 498.6  
Pre-tax profit without non-rec. items  0.0 664 1,225 601 640  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 27.8 31.9 17.5 4.7  
Shareholders equity total  0.0 558 1,398 516 897  
Interest-bearing liabilities  0.0 31.3 5.2 191 10.4  
Balance sheet total (assets)  0.0 883 1,800 780 1,205  

Net Debt  0.0 -327 -1,417 -416 -768  
 
See the entire balance sheet

Volume 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 666 1,246 622 655  
Gross profit growth  0.0% 0.0% 87.1% -50.0% 5.2%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 883 1,800 780 1,205  
Balance sheet change%  0.0% 0.0% 103.9% -56.7% 54.4%  
Added value  0.0 666.0 1,245.8 617.8 654.6  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 26 -6 -29 -26  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 1.0 2.0 3.0 4.0  

Profitability 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 99.8% 99.2% 97.7% 98.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 75.3% 92.1% 47.1% 64.7%  
ROI %  0.0% 112.5% 123.9% 57.6% 79.5%  
ROE %  0.0% 92.8% 97.5% 48.9% 70.5%  

Solidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 63.2% 77.7% 66.2% 74.5%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% -49.1% -113.8% -66.9% -117.3%  
Gearing %  0.0% 5.6% 0.4% 37.0% 1.2%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 1.0% 62.7% 6.9% 2.2%  

Liquidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 2.6 4.4 2.9 3.9  
Current Ratio  0.0 2.6 4.4 2.9 3.9  
Cash and cash equivalent  0.0 358.5 1,422.4 607.6 778.4  

Capital use efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 531.5 1,367.7 498.8 892.4  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0